CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenues:
Total revenues	$ 15	$ 695
Operating expenses:
Research and development	73,001	52,614
General and administrative	11,449	10,820
Total operating expenses	84,450	63,434
Operating loss	(84,435)	(62,739)
Investment and other income, net	5,750	8,943
Net loss	$ (78,685)	$ (53,796)
Basic net loss per common share (in dollars per share)	$ (1.18)	$ (0.81)
Diluted net loss per common share (in dollars per share)	$ (1.18)	$ (0.81)
Shares used in calculating basic net loss per share (in shares)	66,566	66,383
Shares used in calculating diluted net loss per share (in shares)	66,566	66,383
Comprehensive loss:
Net loss	$ (78,685)	$ (53,796)
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities	(1,104)	254
Comprehensive loss	(79,789)	(53,542)
Product development and licensing agreements
Revenues:
Total revenues		50
Contracts and grants
Revenues:
Total revenues	$ 15	$ 645